Long-Term Effects of HIV Exposure and Infection in Children
|HIV Infections HIV Seronegativity|
|Official Title:||Pediatric Late Outcomes Protocol|
|Study Completion Date:||May 2002|
The potential long-term benefits, toxicities, and other adverse outcomes of new anti-HIV therapies cannot be assessed within the time frame of most clinical trials. There is a need to better assess both positive and negative late outcomes and late treatment effects in growing children. This prospective, longitudinal study will evaluate the effects and their impact on children.
Children in this study will include patients who are HIV infected, were exposed to HIV or anti-HIV drugs prior to or at the time of their birth, or children of patients followed at Pediatric AIDS Clinical Trial Group (PACTG) sites. Children will have a study visit every 3 months through the first year of life. After age 1, children who are HIV infected will continue to have study visits every 3 months, while children who are HIV uninfected will have study visits once a year. Study assessments will include complete physical exam, medical history, Tanner staging, neurologic exam, growth and quality of life assessments, and laboratory tests such as hematology, chemistries, and urinalysis. Not all assessments will be performed at each study visit. Patients will be followed until age 24.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006304
Show 92 Study Locations
|Study Chair:||James Oleske|
|Study Chair:||Michael Brady|
|Study Chair:||Wayne Dankner|